Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Corbus Pharmaceuticals Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Corbus Pharmaceuticals Holdings, Inc.’s stock price such as:

• Corbus Pharmaceuticals Holdings, Inc.’s current stock price and volume
• Why Corbus Pharmaceuticals Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for CRBP from analysts
• CRBP’s stock price momentum as measured by its relative strength

About Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Before we jump into Corbus Pharmaceuticals Holdings, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Want to learn more about Corbus Pharmaceuticals Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Corbus Pharmaceuticals Holdings, Inc..

Corbus Pharmaceuticals Holdings, Inc.’s Stock Price as of Market Close

As of August 06, 2026, 4:00 PM, CST, Corbus Pharmaceuticals Holdings, Inc.’s stock price was $9.740.

Corbus Pharmaceuticals Holdings, Inc. is up 1.78% from its previous closing price of $9.570.

During the last market session, Corbus Pharmaceuticals Holdings, Inc.’s stock traded between $9.180 and $9.840. Currently, there are approximately 18.71 million shares outstanding for Corbus Pharmaceuticals Holdings, Inc..

Corbus Pharmaceuticals Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Corbus Pharmaceuticals Holdings, Inc. Stock Price History

Corbus Pharmaceuticals Holdings, Inc.’s (CRBP) price is currently up 8.58% so far this month.

During the month of August, Corbus Pharmaceuticals Holdings, Inc.’s stock price has reached a high of $9.840 and a low of $8.710.

Over the last year, Corbus Pharmaceuticals Holdings, Inc. has hit prices as high as $20.560 and as low as $7.120. Year to date, Corbus Pharmaceuticals Holdings, Inc.’s stock is up 19.66%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Corbus Pharmaceuticals Holdings, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 05, 2026, there were 0 analysts who downgraded Corbus Pharmaceuticals Holdings, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Corbus Pharmaceuticals Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Corbus Pharmaceuticals Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Corbus Pharmaceuticals Holdings, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Corbus Pharmaceuticals Holdings, Inc. (CRBP) by visiting AAII Stock Evaluator.

Relative Price Strength of Corbus Pharmaceuticals Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 05, 2026, Corbus Pharmaceuticals Holdings, Inc. has a weighted four-quarter relative price strength of -2.71%, which translates to a Momentum Score of 45 and is considered to be Average.

Want to learn more about how Corbus Pharmaceuticals Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Corbus Pharmaceuticals Holdings, Inc. Stock Price: Bottom Line

As of August 6, 2026, Corbus Pharmaceuticals Holdings, Inc.’s stock price is $9.740, which is up 1.78% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Corbus Pharmaceuticals Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.